Compare SRE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRE | BDX |
|---|---|---|
| Founded | 1998 | 1897 |
| Country | United States | United States |
| Employees | 15938 | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5B | 51.5B |
| IPO Year | N/A | 1995 |
| Metric | SRE | BDX |
|---|---|---|
| Price | $99.60 | $153.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $100.17 | ★ $188.73 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | 2.64% | ★ 2.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | N/A | $2.22 |
| P/E Ratio | ★ $28.25 | $116.08 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $68.58 | $152.99 |
| 52 Week High | $101.04 | $213.08 |
| Indicator | SRE | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 66.06 | 33.65 |
| Support Level | $90.57 | N/A |
| Resistance Level | N/A | $160.19 |
| Average True Range (ATR) | 1.83 | 3.06 |
| MACD | 0.27 | 0.97 |
| Stochastic Oscillator | 81.64 | 9.02 |
Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure partners, of which Sempra will hold a 25% ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.